Table 4.

Coclassification of different patient populations defined by distinct early molecular parameters

BCR-ABL/GUSIS diagnosis threshold 18.55% OSConcordanceP95% CI
<18.55%>18.55%
Low riskHigh risk
BCR-ABL/ABLIS 3 months
 <10% – low risk110 (55%) 46 (23%)
 >10% – high risk20 (10%) 24 (12%)67%0.003 1.3 - 6.04
BCR-ABL/ABLIS 6 months
 <1% – low risk112 (53.3%)33 (15.7%)
 >1% – high risk26 (12.4%)39 (18.6%)71.9%<0.0012.6 - 10
BCR-ABL/GUSIS diagnosis threshold 18.79% TFSConcordanceP95% CI
<18.79% >18.79%
Low riskHigh risk
BCR-ABL/ABLIS 3 months
 <10% – low risk 112 (56%) 44 (22%)
 >10% – high risk21 (10.5%)23 (11.5%)67.5%0.0031.3 - 5.9
BCR-ABL/ABLIS 6 months
 <1% – low risk114 (54%)31 (14.8%)
 >1% – high risk27 (12.8%)38 (18%)72.3%<0.0012.6 - 10.2
BCR-ABL/GUSIS diagnosis threshold 14.89% FFSConcordanceP95% CI
<14.89% >14.89%
Low riskHigh risk
BCR-ABL/ABLIS 3 months
 <10% – low risk93 (46.5%)63 (31.5%)
 >10% – high risk14 (7%)30 (15%)61.5%0.0021.5 - 7
BCR-ABL/ABLIS 6 months
 <1% - low risk 99 (47.1%) 46 (21.9%)
 >1% - high risk 17 (8.1%) 48 (22.9%)70%<0.0013 -12.4
BCR-ABL/GUSIS diagnosis threshold 15.94% OR or EFSConcordanceP95% CI
<15.94% >15.94%
Low riskHigh risk
BCR-ABL/ABLIS 3 months
 <10% – low risk97 (48.5%)59 (29.5%)
 >10% – high risk15 (7.5%)29 (14.5%)63%0.0011.5 - 6.9
BCR-ABL/ABLIS 6 months
 <1% – low risk 104 (49.5%) 41 (19.5%)
 >1% – high risk 18 (8.6%) 47 (22.5%)71.9%<0.0013.3 -13.5
  • Abbreviation: CI, confidence intervals.